Who is sponsoring NCT03981406?

NCT03981406 is sponsored by University of Minnesota.

What drugs are being tested in NCT03981406?

Interventions in NCT03981406: Palliative Care, Standard of Care.

What condition does NCT03981406 study?

NCT03981406 studies Idiopathic Pulmonary Fibrosis, Depression, Anxiety, Depressive Disorder, Anxiety Disorders, Anxiety Depression.

Is NCT03981406 still recruiting?

NCT03981406 is currently completed. Last updated 29 January 2020.

Last reviewed 2020-01-29 · How we verify

NCT03981406

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Palliative Care and Quality of Life in Idiopathic Pulmonary Fibrosis

Completed NA Last updated 29 January 2020

What this trial tests

NA trial testing Palliative Care in Idiopathic Pulmonary Fibrosis in 22 participants. Completed in 1 March 2019.

Timeline

15 September 2017

Primary endpoint
1 March 2019

1 March 2019

Quick facts

Lead sponsor	University of Minnesota
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	15 September 2017
Primary completion	1 March 2019
Estimated completion	1 March 2019
Sites	1 location across United States

Drugs / interventions tested

Palliative Care — full drug profile →
Standard of Care

Conditions studied

Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →
Depression — all drugs for Depression →
Anxiety — all drugs for Anxiety →
Depressive Disorder — all drugs for Depressive Disorder →

Sponsor

University of Minnesota

Who can join

18 and older, any sex, with Idiopathic Pulmonary Fibrosis or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effects of adding a palliative care intervention for patients with idiopathic pulmonary fibrosis (IPF) to current standard of care. Palliative care is comprehensive, coordinated interdisciplinary care for patients and families facing a potentially life-threatening illness. This consists of specially trained teams of professionals including physicians, nurses, social workers, and chaplains that provide care and support in inpatient and outpatient settings. While the specific assistance and support provided by the Palliative Care Service depends on individual patient and family needs and preferences, it may include: 1. Pain and symptom management 2. Psychosocial and spiritual support 3. Assistance with treatment choices 4. Help in planning for care in the community

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The impact of palliative care on quality of life, anxiety, and depression in idiopathic pulmonary fibrosis: a randomized controlled pilot study.
Janssen K, Rosielle D, Wang Q, Kim HJ. · · 2020 · cited 27× · PMID 31900187 · DOI 10.1186/s12931-019-1266-9

Verify or expand the search:

Other trials of Palliative Care

Trials testing the same drug.

NCT06146738 — The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) · recruiting
NCT05646576 — Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy · NA · recruiting
NCT04248244 — Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma · NA · completed
NCT03540771 — Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD) · NA · completed
NCT03471546 — Early Palliative Care Intervention in Malignant Glioma · NA · completed

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting

Other University of Minnesota trials

Trials by the same sponsor.

NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03981406 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
Last refreshed: 29 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03981406.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing